9 analysts have shared their evaluations of Addus HomeCare ADUS during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 8 | 0 | 0 | 0 |
Last 30D | 0 | 2 | 0 | 0 | 0 |
1M Ago | 0 | 1 | 0 | 0 | 0 |
2M Ago | 0 | 1 | 0 | 0 | 0 |
3M Ago | 1 | 4 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $141.56, with a high estimate of $150.00 and a low estimate of $137.00. This upward trend is evident, with the current average reflecting a 4.56% increase from the previous average price target of $135.38.
Investigating Analyst Ratings: An Elaborate Study
The standing of Addus HomeCare among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Tao Qiu | Macquarie | Maintains | Outperform | $139.00 | $139.00 |
Matthew Gillmor | Keybanc | Announces | Overweight | $150.00 | - |
Michael Wiederhorn | Oppenheimer | Raises | Outperform | $145.00 | $140.00 |
Ben Hendrix | RBC Capital | Maintains | Outperform | $141.00 | $141.00 |
Ben Hendrix | RBC Capital | Raises | Outperform | $141.00 | $129.00 |
Ryan Langston | TD Cowen | Raises | Buy | $137.00 | $128.00 |
Scott Fidel | Stephens & Co. | Raises | Overweight | $143.00 | $138.00 |
Michael Wiederhorn | Oppenheimer | Raises | Outperform | $140.00 | $130.00 |
Scott Fidel | Stephens & Co. | Maintains | Overweight | $138.00 | $138.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Addus HomeCare. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Addus HomeCare compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Addus HomeCare's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Addus HomeCare's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Addus HomeCare analyst ratings.
Get to Know Addus HomeCare Better
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
Addus HomeCare: Financial Performance Dissected
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Addus HomeCare's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 10.36%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Addus HomeCare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.3%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.2%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Addus HomeCare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.7% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.